Synthetic Cannabinoids Influence the Invasion of Glioblastoma Cell Lines in a Cell- and Receptor-Dependent Manner.
cannabinoids
glioblastoma
invasiveness
micro-RNA
pAkt
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
31 Jan 2019
31 Jan 2019
Historique:
received:
17
01
2019
revised:
28
01
2019
accepted:
28
01
2019
entrez:
3
2
2019
pubmed:
3
2
2019
medline:
3
2
2019
Statut:
epublish
Résumé
The current treatment of glioblastoma is not sufficient, since they are heterogeneous and often resistant to chemotherapy. Earlier studies demonstrated effects of specific cannabinoid receptor (CB) agonists on the invasiveness of glioblastoma cell lines, but the exact mechanism remained unclear. Three human glioblastoma cell lines were treated with synthetic CB ligands. The effect of cannabinoids on microRNAs (miRs), Akt, and on the expression of proliferation and apoptosis markers were analyzed. Furthermore, in a model of organotypic hippocampal slice cultures cannabinoid mediated changes in the invasiveness were assessed. MicroRNAs and the activation of Akt which are related to cell migration, apoptosis, and proliferation were evaluated and found not to be associated with changes in the invasiveness after treatment with CB ligands. Also proliferation and/or apoptosis were not altered after treatment. The effects of cannabinoids on invasiveness could be blocked by the application of receptor antagonists and are likely mediated via CB₁/CB₂. In conclusion, our results suggest that cannabinoids can influence glioblastoma cell invasion in a receptor and cell type specific manner that is independent of proliferation and apoptosis. Thus, cannabinoids can potentially be used in the future as an addition to current therapy.
Identifiants
pubmed: 30709059
pii: cancers11020161
doi: 10.3390/cancers11020161
pmc: PMC6406558
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Wilhelm-Roux- Programm of the Medical Faculty Martin Luther University Halle-Wittenberg.
ID : 29/18
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Cell Death Differ. 1999 Feb;6(2):99-104
pubmed: 10200555
Brain Pathol. 1999 Jul;9(3):469-79
pubmed: 10416987
Biochem J. 2000 Apr 15;347(Pt 2):369-73
pubmed: 10749665
Trends Pharmacol Sci. 2000 Jun;21(6):218-24
pubmed: 10838609
Biochem Pharmacol. 2000 Dec 15;60(12):1807-13
pubmed: 11108795
J Neurosurg. 2001 Jun;94(6):978-84
pubmed: 11409528
Cancer Res. 2001 Aug 1;61(15):5784-9
pubmed: 11479216
J Cell Sci. 2001 Jul;114(Pt 13):2375-82
pubmed: 11559746
J Natl Cancer Inst. 1975 Sep;55(3):597-602
pubmed: 1159836
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Blood. 2002 Jul 15;100(2):627-34
pubmed: 12091357
Cell Signal. 2003 Sep;15(9):851-9
pubmed: 12834810
Nat Rev Cancer. 2003 Oct;3(10):745-55
pubmed: 14570037
J Pharmacol Exp Ther. 2004 Mar;308(3):838-45
pubmed: 14617682
Cancer Res. 2004 Mar 15;64(6):1943-50
pubmed: 15026328
Br J Pharmacol. 2005 Apr;144(8):1032-6
pubmed: 15700028
Gut. 2005 Dec;54(12):1741-50
pubmed: 16099783
Exp Cell Res. 2006 Feb 15;312(4):363-73
pubmed: 16343481
Cancer Cell. 2006 Apr;9(4):301-12
pubmed: 16616335
Mol Pharmacol. 2006 Oct;70(4):1298-306
pubmed: 16822929
Cell Mol Life Sci. 2006 Sep;63(17):2057-66
pubmed: 16909207
Br J Pharmacol. 2007 Mar;150(5):613-23
pubmed: 17245363
Cell. 2007 May 18;129(4):665-79
pubmed: 17512402
Oncogene. 2008 Jan 10;27(3):339-46
pubmed: 17621270
Br J Pharmacol. 2007 Dec;152(7):1092-101
pubmed: 17876302
Acta Oncol. 2008;47(6):1062-70
pubmed: 17934890
Mol Neurobiol. 2007 Aug;36(1):60-7
pubmed: 17952650
J Neurochem. 2008 Feb;104(4):1132-43
pubmed: 17986216
Expert Rev Neurother. 2008 Jan;8(1):37-49
pubmed: 18088200
Cancer Res. 2008 Mar 15;68(6):1945-52
pubmed: 18339876
Addict Biol. 2008 Jun;13(2):147-59
pubmed: 18482430
Mol Cell Biol. 2008 Sep;28(17):5369-80
pubmed: 18591254
Oncogene. 2008 Sep 18;27(41):5416-30
pubmed: 18794877
Cancer Res. 2008 Oct 1;68(19):8164-72
pubmed: 18829576
BMC Syst Biol. 2008 Dec 17;2:108
pubmed: 19091071
J Cell Mol Med. 2009 Jan;13(1):39-53
pubmed: 19175699
J Neurosci. 2009 Apr 8;29(14):4564-70
pubmed: 19357281
J Clin Invest. 2009 May;119(5):1359-72
pubmed: 19425170
J Mol Endocrinol. 2010 Feb;44(2):75-85
pubmed: 19620237
Sci Signal. 2009 Sep 08;2(87):re6
pubmed: 19738203
Brain Pathol. 2010 May;20(3):539-50
pubmed: 19775293
CNS Neurol Disord Drug Targets. 2009 Dec;8(6):422-31
pubmed: 19839935
Lab Invest. 2010 Feb;90(2):144-55
pubmed: 20048743
Mol Cancer Ther. 2010 Jan;9(1):180-9
pubmed: 20053780
PLoS One. 2010 Jan 14;5(1):e8702
pubmed: 20090845
Cancer Cell. 2010 Jan 19;17(1):98-110
pubmed: 20129251
Exp Neurol. 2010 Jul;224(1):56-65
pubmed: 20353775
Br J Pharmacol. 2010 Jun;160(3):762-71
pubmed: 20590578
Pharmacol Rev. 2010 Dec;62(4):588-631
pubmed: 21079038
Mol Cancer Ther. 2011 Jan;10(1):90-103
pubmed: 21220494
Br J Pharmacol. 2011 Aug;163(7):1520-32
pubmed: 21480865
Br J Pharmacol. 2012 Apr;165(8):2561-74
pubmed: 21615724
Cell Signal. 2011 Oct;23(10):1515-27
pubmed: 21620960
Chin J Cancer. 2011 Jun;30(6):371-80
pubmed: 21627859
Cancer Res. 2011 Jun 15;71(12):4055-60
pubmed: 21628493
J Neurooncol. 2012 Apr;107(2):359-64
pubmed: 22045118
Nat Rev Cancer. 2012 May 04;12(6):436-44
pubmed: 22555283
Int J Cancer. 2013 Jan 15;132(2):308-14
pubmed: 22700458
Genes Cancer. 2012 Jan;3(1):3-15
pubmed: 22893786
Mol Neurobiol. 2013 Feb;47(1):131-44
pubmed: 23054677
Cancer Res. 2013 Mar 1;73(5):1559-69
pubmed: 23243024
Trends Pharmacol Sci. 2013 May;34(5):273-82
pubmed: 23602129
Nat Rev Neurosci. 2013 Oct;14(10):722-9
pubmed: 23985834
Mol Cancer Ther. 2013 Nov;12(11):2483-93
pubmed: 24030632
J Biol Chem. 2013 Dec 27;288(52):36810-26
pubmed: 24202177
PLoS One. 2013 Oct 21;8(10):e76918
pubmed: 24204703
Neuro Oncol. 2013 Dec;15(12):1696-709
pubmed: 24220141
PLoS One. 2014 Apr 03;9(4):e93954
pubmed: 24699635
FEBS Open Bio. 2014 May 22;4:485-95
pubmed: 24944883
Nat Rev Neurosci. 2014 Jul;15(7):455-65
pubmed: 24946761
Biochem Biophys Res Commun. 2014 Sep 5;451(4):516-21
pubmed: 25111814
Neuroscience. 2014 Oct 10;278:222-36
pubmed: 25158675
Cell Death Dis. 2015 Jan 15;6:e1601
pubmed: 25590811
Sci Rep. 2015 Jan 27;5:7979
pubmed: 25623281
Int J Oncol. 2015 Apr;46(4):1601-8
pubmed: 25626081
Am J Cancer Res. 2014 Dec 15;5(1):201-18
pubmed: 25628931
Clin Pharmacol Ther. 2015 Jun;97(6):587-96
pubmed: 25669486
Arch Pharm Res. 2015 Mar;38(3):423-34
pubmed: 25683176
Br J Cancer. 2015 Mar 31;112(7):1241-6
pubmed: 25756397
Front Oncol. 2015 Mar 03;5:55
pubmed: 25785247
J Neuroimmune Pharmacol. 2015 Jun;10(2):255-67
pubmed: 25916739
Neuro Oncol. 2016 Jan;18(1):58-69
pubmed: 26433199
Folia Neuropathol. 2015;53(3):236-44
pubmed: 26443314
Mol Cell Endocrinol. 2016 Mar 5;423:67-76
pubmed: 26773729
Genome Res. 2016 Apr;26(4):554-65
pubmed: 26821571
Brain Tumor Pathol. 2016 Apr;33(2):77-88
pubmed: 26968172
Curr Oncol. 2016 Mar;23(2):S23-32
pubmed: 27022311
Cell Adh Migr. 2017 Jan 2;11(1):54-67
pubmed: 27149140
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Neuropharmacology. 2016 Sep;108:345-52
pubmed: 27179908
Cancer Med. 2016 Aug;5(8):1917-46
pubmed: 27282910
Neuro Oncol. 2017 Jan;19(1):55-65
pubmed: 27471108
Front Cell Neurosci. 2017 Jan 04;10:294
pubmed: 28101004
Sci Rep. 2017 Feb 13;7:42157
pubmed: 28191815
J Vis Exp. 2017 Aug 27;(126):
pubmed: 28872113
Oncotarget. 2017 Apr 13;8(33):54459-54471
pubmed: 28903355
Int J Mol Sci. 2017 Sep 18;18(9):null
pubmed: 28926987
Oncotarget. 2017 Aug 11;8(40):69185-69197
pubmed: 28978189
Oncotarget. 2017 May 27;8(43):74068-74095
pubmed: 29088769
Cancer Res. 1994 Feb 1;54(3):649-52
pubmed: 8306326
J Neurooncol. 1998 Aug;39(1):19-32
pubmed: 9760067
FEBS Lett. 1998 Sep 25;436(1):6-10
pubmed: 9771884
Int J Cancer. 1998 Dec 18;79(6):640-4
pubmed: 9842975